Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 969K | 917K | 116K | 13K |
| Gross Profit | 995K | 740K | 390K | -86K | 2K |
| Operating Income | -8M | -11M | -9M | -5M | -2M |
| EBITDA | -8M | -10M | -9M | -5M | -2M |
| Net Income | -8M | -11M | -9M | -5M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.78
-8.24% today
1Y Change
-2.50%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PetVivo Holdings, Inc. (PETV) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.78 and down 2.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +16.9%, EPS growth of +47.4%, a dividend yield of 0.0%. What stands out right now is revenue +16.9%, EPS +47.4%, free cash flow +23.9% with operating margin -735.9% and ROIC -237.2%. Valuation already assumes a fairly strong business story at price/sales 19.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PETV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PETV
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PETV Max Drawdown
-56.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PETV and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$12.6K
-89.1% YoY
FY Net Income
-$3.8M
+24.1% YoY
Free Cash Flow
-$1.2M
+72.3% YoY
Revenue Growth
+16.9%
EPS Growth
+47.4%
Gross Margin
66.0%
Net Margin
-893.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1M | 969K | 917K | 116K | 13K |
| Gross Profit | 995K | 740K | 390K | -86K | 2K |
| Operating Income | -8M | -11M | -9M | -5M | -2M |
| EBITDA | -8M | -10M | -9M | -5M | -2M |
| Net Income | -8M | -11M | -9M | -5M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 228K | 87K | 475K | 6M | 24K |
| Total Assets | 9M | 3M | 2M | 7M | 835K |
| Total Liabilities | 5M | 2M | 2M | 1M | 2M |
| Shareholder Equity | 4M | 686K | 725K | 6M | -897K |
| Total Debt | 3M | 1M | 345K | 333K | 733K |
| Net Debt | 3M | 1M | -130K | -6M | 709K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+74.9% YoY
Capital Expenditures
160K
+12.6% YoY
Free Cash Flow
1M
+72.3% YoY
Key ratios
Gross Margin
66.0%
Operating Margin
-735.9%
Net Margin
-893.3%
ROE
-256.1%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.